Acute Myocardial Infarction, Contrast-Induced Nephropathy
Conditions
Keywords
Contrast-induced nephropathy, Acute myocardial infarction, Primary coronary angioplasty
Brief summary
Patients with acute myocardial infarction undergoing primary angioplasty are at high risk for renal injury due to the toxic effect of contrast agents. Patients developing renal dysfunction after primary angioplasty have worse outcome. To investigate the role of the antioxidant N-acetylcysteine (NAC) in preventing renal injury in angioplasty, we randomized 352 consecutive patients undergoing primary angioplasty into three groups: the first group received NAC at standard dose (NAC group, 600 mg i.v. bolus before primary angioplasty, followed by oral 600 mg twice daily for the following 48 hours; n=115), the second group received NAC at double dose (DD-NAC group; 1,200 mg i.v. bolus and oral 1,200 mg twice daily for 48 hours; n=118), and the last group received placebo (controls; n=119).
Interventions
DRUGintravenous and oral N-acetylcysteine
Sponsors
University of Milan
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
Consecutive patients admitted to the Coronary Care Unit for ST-segment elevation acute myocardial infarction undergoing primary angioplasty. Patients were included if they presented within 12 hours (18 hours for acute myocardial infarction complicated by cardiogenic shock) from the onset of symptoms. -
Exclusion criteria
Patients in chronic peritoneal or hemodialytic treatment and those with known allergy to N-acetylcysteine. \-
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of contrast-induced nephropathy | — |
Secondary
| Measure | Time frame |
|---|---|
| In-hospital major clinical adverse events including death | — |
Countries
Italy
Outcome results
None listed